Lv1
50 积分 2024-11-22 加入
Mechanisms, precision therapies, and technological frontiers in coronary atherosclerosis: a comprehensive review
10天前
已完结
Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention
2个月前
已完结
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
2个月前
已完结
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China
4个月前
已完结
Gene expression of coregulators of proprotein convertase subtilisin/kexin type 9 in pateints with coronary artery disease
4个月前
已关闭
Expanding Our Understanding of Plaque Stabilization With PCSK9 Inhibitors
5个月前
已完结
Combinatorial, additive and dose-dependent drug–microbiome associations
5个月前
已完结
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China
6个月前
已完结
Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
6个月前
已完结
Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults
7个月前
已完结
皖公网安备34019202002308
